<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19266088</article-id><article-id pub-id-type="pmc">2648639</article-id><article-id pub-id-type="doi">10.1155/2008/626340</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Strong Expression of Chemokine Receptor <italic>CXCR</italic>4 by Renal Cell Carcinoma Correlates with Advanced Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wehler</surname><given-names>Thomas C.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Graf</surname><given-names>Claudine</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Biesterfeld</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>Walburgis</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schadt</surname><given-names>J&#x000f6;rg</given-names></name><xref ref-type="aff" rid="I4"><sup>4, 5</sup></xref><xref ref-type="aff" rid="I5"/></contrib><contrib contrib-type="author"><name><surname>Gockel</surname><given-names>Ines</given-names></name><xref ref-type="aff" rid="I4"><sup>4, 5</sup></xref><xref ref-type="aff" rid="I5"/></contrib><contrib contrib-type="author"><name><surname>Berger</surname><given-names>Martin R.</given-names></name><xref ref-type="aff" rid="I6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Th&#x000fc;roff</surname><given-names>Joachim W.</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Galle</surname><given-names>Peter R.</given-names></name><xref ref-type="aff" rid="I7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moehler</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="I7"><sup>7, 5</sup></xref><xref ref-type="aff" rid="I5"/></contrib><contrib contrib-type="author"><name><surname>Schimanski</surname><given-names>Carl C.</given-names></name><xref ref-type="aff" rid="I7"><sup>7, 5</sup></xref><xref ref-type="aff" rid="I5"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Third Department of Internal Medicine, Johannes Gutenberg University of Mainz, 55131 Mainz, Germany</aff><aff id="I2"><sup>2</sup>Institute of Pathology, Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany</aff><aff id="I3"><sup>3</sup>Department of Urology, Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany</aff><aff id="I4"><sup>4</sup>Institute of Surgery, Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany</aff><aff id="I5"><sup>5</sup>Interdisciplinary Translational Oncological Laboratory (ITOL), Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany</aff><aff id="I6"><sup>6</sup>Unit of Toxicology and Chemotherapy, German Cancer Research Center, 69120 Heidelberg, Germany</aff><aff id="I7"><sup>7</sup>First Department of Internal Medicine, Johannes Gutenberg University of Mainz, 55131 Mainz, Germany</aff><author-notes><corresp id="cor1">*Carl C. Schimanski: <email>dr_schimanski@yahoo.de</email></corresp><fn fn-type="other"><p>Recommended by Meenhard Herlyn</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>626340</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2008</year></date><date date-type="rev-recd"><day>9</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>29</day><month>9</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Thomas C. Wehler et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Diverse chemokines and their receptors have been associated with tumor growth, tumor dissemination, and local immune escape. In different tumor entities, the level of chemokine receptor <italic>CXCR</italic>4 expression has been linked with tumor progression and decreased survival. The aim of this study was to evaluate the influence of <italic>CXCR</italic>4 expression on the progression of human renal cell carcinoma. <italic>CXCR</italic>4 expression of renal cell carcinoma was assessed by immunohistochemistry in 113 patients. Intensity of <italic>CXCR</italic>4 expression was correlated with both tumor and patient characteristics. Human renal cell carcinoma revealed variable intensities of <italic>CXCR</italic>4 expression. Strong <italic>CXCR</italic>4 expression of renal cell carcinoma was significantly associated with advanced T-status (<italic>P</italic> = .039), tumor dedifferentiation (<italic>P</italic> = .0005), and low hemoglobin (<italic>P</italic> = .039). In summary, strong <italic>CXCR</italic>4 expression was significantly associated with advanced dedifferentiated renal cell carcinoma.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Renal  cell  carcinoma  (RCC) is the  sixth leading causeof cancer-related deaths in the Western world and comprises 2-3% of all newlydiagnosed malignancies in adults. Among the different kidney neoplasms, itrepresents with 85% the largest fraction [<xref ref-type="bibr" rid="B1">1</xref>]. The age-adjusted incidence of RCCin Western nations is 5&#x02013;12/100 000 inwomen or men, respectively, with a peak incidence in the 6th decade [<xref ref-type="bibr" rid="B2">2</xref>]. Inpractice, the only curable treatment is nephrectomy performed in early stages ofthe disease. However, about 30&#x02013;50% of patientshave already metastases at presentation, and approximately one third of the nephrectomizedpatients relapse and progress with metastatic disease. The preferential sitesof metastasis are the regional lymph nodes, the lung, the liver, and the bones. Survival strongly depends on the tumor stage at presentation. The 5-yearsurvival rate is approximately 50%, whereas the median survival in case ofmetastasis is less than one year [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>]. The currentstandard treatment for metastasized RCC consists of the application of <italic>IFN</italic>-<italic>&#x003b1;</italic>and <italic>IL</italic>-2 [<xref ref-type="bibr" rid="B6">6</xref>]. Recently, phase II clinical trials using receptor-tyrosinekinase (<italic>RTK</italic>) inhibitors have shown more promising results and lead toapproval by the Food and Drug Administration (FDA) and European MedicinesAgency (EMEA) [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>In vivo and in vitro results from different tumorentities suggest that organ-specific metastasis is partially governed byinteractions of chemokine receptors on cancer cells and their correspondingchemokines expressed in  target organs and the tumor bed. This process isconsidered to direct lymphatic and hematogenous spread and furthermore influences thesites of metastatic growth [<xref ref-type="bibr" rid="B7">7</xref>]. Chemokines and their respectiveG-protein-coupled receptors were initially described to mediate different pro-and anti-inflammatory responses [<xref ref-type="bibr" rid="B8">8</xref>]. In particular, the high expression ofstromal cell derived factor 1<italic>&#x003b1;</italic> (<italic>SDF</italic>-1<italic>&#x003b1;</italic>), also known as <italic>CXCL</italic>12, by endothelialcells, biliary epithelial cells, bone marrow stromal cells, and lymph nodesresults in a chemotactic gradient attracting <italic>CXCR</italic>4 expressinglymphocytes into those organs [<xref ref-type="bibr" rid="B9">9</xref>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>]. Most recently, <italic>CXCR</italic>4 has shifted into focus as itis the most common chemokine receptor expressed on cancer cells [<xref ref-type="bibr" rid="B16">16</xref>]. It wassuggested to play an important role in tumor spread of colorectal, breast, and oralsquamous cell carcinoma as all of them commonly metastasize to <italic>SDF</italic>-1<italic>&#x003b1;</italic> expressing organs [<xref ref-type="bibr" rid="B17">17</xref>&#x02013;<xref ref-type="bibr" rid="B20">20</xref>]. Dataobtained from in vitro as well as from murine in vivo models, analyzing themetastatic ability of <italic>CXCR</italic>4 in expressing cancer cells, underlined thekey role of <italic>CXCR</italic>4 for tumor cell malignancy, as activation of <italic>CXCR</italic>4 by <italic>SDF</italic>-1<italic>&#x003b1;</italic> induced migration, invasion, and angiogenesis of cancercells [<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Therefore, we evaluated theexpression of <italic>CXCR</italic>4 in renal cancer cell lines and specimens andcorrelated these results with the patients' clinicopathological parameters andsurvival.</p></sec><sec sec-type="section" id="sec2"><title>2. Materials and Methods</title><sec id="subsec2.1"><title>2.1. Tissue Samples</title><p>Renal cellcarcinoma samples wereintraoperatively obtained from 113 patients with renal clear cell carcinoma whounderwent surgery at the Department of Urology of the University of Mainz. The morphological classification of the carcinomas was conducted according toWorld Health Organization (WHO) specifications. Patients were followed up on aregular basis depending on the procedure performed.</p></sec><sec id="subsec2.2"><title>2.2. Immunohistochemical Staining</title><p>The  avidin-biotin-complex method(LSAB+ System-HRP Kit,  Dako Cytomation, Hamburg, Germany) was used todetect the protein <italic>CXCR</italic>4 (anti-<italic>CXCR</italic>4, dilution 1 : 300; CapralogicsInc., Mass, USA). Formalin-fixed and paraffin-embedded tissues were deparaffinized andsubsequently microwaved (600 W, 15 minutes) in citrate buffer (ph 6.0). Afterpreincubation with hydrogen peroxide (LSAB+ System-HRP Kit, Dako Cytomation, Hamburg,Germany) and human AB plasma (Department of Transfusion, University of Mainz,Mainz, Germany), the primary antibodies were applied for one hour at roomtemperature. After incubation with the secondary antibody (LSAB+ System-HRPKit, Dako Cytomation, Hamburg, Germany),the avidin-biotin complex was added and the enzyme activity was visualized withdiaminobenzidine (LSAB+ System-HRP Kit, Dako Cytomation, Hamburg, Germany). Counterstaining was performed with haematoxylin (Roth, Karlsruhe, Germany). For negative controls only the secondary antibody was used. A negative controlwas performed for each sample (<italic>N</italic> = 113). For positive controls formalin-fixed andparaffin-embedded tissue samples of the human spleen were applied.</p></sec><sec id="subsec2.3"><title>2.3. Evaluation of Immunostaining</title><p>Immunostaining was evaluated by three authorsindependently (T.C. Wehler, C. Graf, S. Biesterfeld), blinded to patientoutcome and all clinicopathologic findings. The immunohistochemical stainingwas analyzed according to a scoring method as previously validated anddescribed [<xref ref-type="bibr" rid="B17">17</xref>]. The tumors were classified into four groups based onthe homogeneous staining intensity: 0, absent; 1, weak; 2, intermediate; 3,strong staining.  In the case of heterogeneous staining within the same sample, the respective higher score was chosen, if more than 50% of cells revealed a higher staining intensity. If expression intensity was exactly in between two scores, the authors agreed on 0.5 point-steps. If evaluationsdid not agree, specimens were re-evaluated and reclassified according to theassessment given most frequently by the observers.</p></sec><sec id="subsec2.4"><title>2.4. Statistics</title><p>The correlation of <italic>CXCR</italic>4 stainingintensity with clinicopathological patterns was assessed with the <italic>&#x003c7;</italic><sup>2</sup> test and with the unpaired Student <italic>t</italic>-test (one/two sided), when appropriate. Survival rates were visualizedapplying Kaplan-Meier curves, and <italic>P</italic>-values were determined by log-ranktest. <italic>P</italic> &#x0003c; .05 was considered significant and <italic>P</italic> &#x0003c; .001highly significant in all statistical analyses.</p></sec></sec><sec sec-type="section" id="sec3"><title>3. Results</title><sec id="subsec3.1"><title>3.1. Tumor Characteristics and Patient Profiles</title><p>The selected group of patients represents thetypical characteristics of renal cell carcinoma in industrialized countries.</p></sec><sec id="subsec3.2"><title>3.2. Immunohistochemical Staining of <italic>CXCR</italic>4 in Renal Cell Carcinoma</title><p>The  staining of normal human kidney tissue for <italic>CXCR</italic>4 revealed a cytoplasmatic expression and in only few specimens an additional weak membranous location of <italic>CXCR</italic>4 (see <xref ref-type="fig" rid="fig1">Figure 1</xref>). A nuclear staining of <italic>CXCR</italic>4 was not observed. In renalcell carcinoma, the respective expression rate for <italic>CXCR</italic>4 was 100%(113/113) and varied from weak (34%), intermediate (42%), to strong (24%). Negative controls of human renal cancer remained negative for all tissuesamples (<italic>N</italic> = 113, not shown). Glomeruli did not reveal any <italic>CXCR</italic>4 expression and thus served as internal negative control. As internal positive control, splenic lymphocytes(strong <italic>CXCR</italic>4 expression) and tubuli cells (intermediate <italic>CXCR</italic>4 expression) were used. Similarly, inflammatory infiltrates in kidney tissue (data not shown) depicteda strong <italic>CXCR</italic>4 expression.</p></sec><sec id="subsec3.3"><title>3.3. Relevance of <italic>CXCR</italic>4 Expression in Renal Cell Carcinoma</title><p>Strong <italic>CXCR</italic>4 expression significantly correlated withdedifferentiated (<italic>P</italic> = .0005) and progressed renal cell carcinoma, indicated by T-status (<italic>P</italic> = .039;see <xref ref-type="table" rid="tab1">Table 1</xref>). Furthermore, strong <italic>CXCR</italic>4 expression revealed asignificant association with low hemoglobin values (<italic>P</italic> = .039) and a nonsignificant trend towardsincreased thrombocytes (<italic>P</italic> = .089/<italic>P</italic> = .18, resp.). Nocorrelation was seen for age, size, survival, or creatinine values.</p></sec></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>Theexpression of the chemokine receptor <italic>CXCR</italic>4 has been reported in various epithelial, mesenchymal, and hematopoietic tumors. In several entities, its expression was linked to tumor dissemination and poorprognosis [<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>]. <italic>CXCR</italic>4 expression can be increased as a result of intracellular second messengers suchas calcium [<xref ref-type="bibr" rid="B26">26</xref>] and cyclic AMP [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>] by the inactivation of the tumorsuppressor gene <italic>p</italic>53 andoverexpression of <italic>NF<italic>&#x003ba;</italic>B</italic> [<xref ref-type="bibr" rid="B29">29</xref>&#x02013;<xref ref-type="bibr" rid="B31">31</xref>], by cytokines like <italic>IL</italic>-2, <italic>IL</italic>-10, or <italic>TGF</italic>-1<italic>&#x003b2;</italic> [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B32">32</xref>] and by growth factors such as <italic>VEGF</italic> and <italic>EGF</italic> [<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>]. In addition, Staller and colleagues coulddemonstrate that <italic>CXCR</italic>4 is a hypoxiainducible gene with a <italic>HIF</italic>-1<italic>&#x003b1;</italic> binding domain, and that its overexpressionin clear-cell renal cell carcinoma is due to a loss-of-function of the vonHippel-Lindau (<italic>VHL</italic>) tumor suppressorprotein, which under normoxic conditions directs <italic>HIF</italic>-1<italic>&#x003b1;</italic> to <italic>ubiquitin</italic>-mediated degradation [<xref ref-type="bibr" rid="B35">35</xref>]. Loss of <italic>VHL</italic> stabilizes <italic>HIF</italic>-1<italic>&#x003b1;</italic> leading toincreased expression of hypoxia-response genes including <italic>VEGFA</italic>, <italic>CXCR4,</italic> its ligand <italic>SDF</italic>1<italic>&#x003b1;</italic>, and <italic>HIF</italic>-1<italic>&#x003b1;</italic> itself [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. They alsoreported a positive correlation between strong <italic>CXCR</italic>4 expression and poortumor-specific survival independent of tumor stage and differentiation grade. The latter is in contrast to the results obtained in our study.</p><p>We analyzedthe expression profile of <italic>CXCR</italic>4 in aseries of human renal cell carcinoma cell lines and 113 patients' samples forwhich exact tumor staging and followup data were available and correlated theexpression profile with clinicopathological data. The human renal cellcarcinoma tumor samples that are analyzed revealed varying intensities of <italic>CXCR</italic>4 expression ranging from weak tostrong, as previously described for pancreatic and colorectal cancer [<xref ref-type="bibr" rid="B38">38</xref>]. Interestingly, <italic>CXCR</italic>4 expression was downregulated in 34% and upregulatedin 24% of renal cell carcinoma as compared to original tubuli cells. 42% ofcancers revealed the identical expression intensity of <italic>CXCR</italic>4 as tubulicells. A cytoplasmatic staining of <italic>CXCR</italic>4 was observed in all cancers, whereas fewer cases depicted an additionalmembranous  localization of <italic>CXCR</italic>4. These observations are in line with a recently published study by Zagzag and coworkers [<xref ref-type="bibr" rid="B44">44</xref>]. Furthermore, it was reported that <italic>CXCR</italic>4 surface expression was higher in permanent cell lines than in primary tumor samples [<xref ref-type="bibr" rid="B39">39</xref>]. Noteworthy, an inducible translocation of <italic>CXCR</italic>4 from the cytoplasm to the membranehas been reported previously in [<xref ref-type="bibr" rid="B29">29</xref>]. In addition, at least in breast cancercells, inhibited <italic>CXCR</italic>4 ubiquitinationwas described as another mechanism contributing to increased <italic>CXCR</italic>4 surface levels [<xref ref-type="bibr" rid="B40">40</xref>].</p><p>In ourrenal cell carcinoma patients, a strong <italic>CXCR</italic>4 expression wassignificantly associated as well with progressed cancer as indicated by theT-status as with dedifferentiation. Our results are furthermore in line withrecent reports from our group and others, describing a similar effect of <italic>CXCR</italic>4 on disease progression in othertumor entities [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. Hence, our data suggest a relevant influence of <italic>CXCR</italic>4 on proliferation anddifferentiation of renal cell carcinoma with regard to the in vivo situation. This hypothesis is strengthened by observations in a murine model, where themetastatic capability of <italic>CXCR</italic>4-expressingRCC cells strongly correlated with <italic>CXCR</italic>4 protein level on cancer cells and the <italic>SDF</italic>-1<italic>&#x003b1;</italic> expression in the target organs [<xref ref-type="bibr" rid="B23">23</xref>]. Therefore, <italic>CXCR</italic>4-expressing cancer cells arecertainly attracted to the typical &#x0201c;homing organs&#x0201d; such as lungs, bone marrow,liver, and lymph-nodes showing a high SDF-1<italic>&#x003b1;</italic> expression [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B42">42</xref>]. A pathophysiologicalrelevant fact worthwhile to be mentioned is that endothelial cells coexpress <italic>SDF</italic>-1<italic>&#x003b1;</italic> and <italic>VCAM</italic>-1,thus mediating tumor-cell/endothelial cell attachment. <italic>CXCR</italic>4 activation by <italic>SDF</italic>-1<italic>&#x003b1;</italic> induces <italic><italic>&#x003b2;</italic>-integrin</italic> expression, binding <italic>VCAM</italic>-1 on endothelial cell[<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>]. Similar pathophysiological processes must be proposed for renal cellcarcinoma dissemination.</p><p>Therefore, <italic>CXCR</italic>4 might be an interestingtherapeutic target in a multimodal therapy of renal clear cell carcinoma.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CXCR4:</term><def><p>Chemokine receptor 4</p></def></def-item><def-item><term>EMEA:</term><def><p>European Medicines Agency</p></def></def-item><def-item><term>FDA:</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term>HIF:</term><def><p>Hypoxia induced factor</p></def></def-item><def-item><term>IL:</term><def><p>Interleukin</p></def></def-item><def-item><term>RCC:</term><def><p>Renal cell carcinoma</p></def></def-item><def-item><term>RTK:</term><def><p>Receptor-tyrosine kinases</p></def></def-item><def-item><term>SDF-1<italic>&#x003b1;</italic>:</term><def><p>Stromal cell derived factor 1<italic>&#x003b1;</italic></p></def></def-item><def-item><term>VHL:</term><def><p>Von Hippel Lindau</p></def></def-item><def-item><term>WHO:</term><def><p>World health organization.</p></def></def-item></def-list></glossary><ack><title>Acknowledgment</title><p>The authorsthank the Sparkasse Pforzheim-Calw, Pforzheim, Germany, forsupporting their work.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allinen</surname><given-names>M</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Molecular characterization of the tumor microenvironment in breast cancer</article-title><source><italic>Cancer Cell</italic></source><year>2004</year><volume>6</volume><issue>1</issue><fpage>17</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15261139</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>RJ</given-names></name></person-group><article-title>Chemotherapy for renal cell carcinoma</article-title><source><italic>Seminars in Oncology</italic></source><year>2000</year><volume>27</volume><issue>2</issue><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">10768596</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>HRH</given-names></name></person-group><article-title>Expanding role of chemokines and their receptors in cancer</article-title><source><italic>Expert Review of Anticancer Therapy</italic></source><year>2003</year><volume>3</volume><issue>6</issue><fpage>749</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">14686697</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baggiolini</surname><given-names>M</given-names></name></person-group><article-title>Chemokines and leukocyte traffic</article-title><source><italic>Nature</italic></source><year>1998</year><volume>392</volume><issue>6676</issue><fpage>565</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">9560152</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow?</article-title><source><italic>The Lancet</italic></source><year>2001</year><volume>357</volume><issue>9255</issue><fpage>539</fpage><lpage>545</lpage></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleul</surname><given-names>CC</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name></person-group><article-title>B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement</article-title><source><italic>Journal of Experimental Medicine</italic></source><year>1998</year><volume>187</volume><issue>5</issue><fpage>753</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">9480985</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brigati</surname><given-names>C</given-names></name><name><surname>Noonan</surname><given-names>DM</given-names></name><name><surname>Albini</surname><given-names>A</given-names></name><name><surname>Benelli</surname><given-names>R</given-names></name></person-group><article-title>Tumors and inflammatory infiltrates: friends or foes?</article-title><source><italic>Clinical and Experimental Metastasis</italic></source><year>2002</year><volume>19</volume><issue>3</issue><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">12067205</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>M</given-names></name><name><surname>Glodek</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells</article-title><source><italic>Oncogene</italic></source><year>2003</year><volume>22</volume><issue>50</issue><fpage>8093</fpage><lpage>8101</lpage><pub-id pub-id-type="pmid">14603250</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardones</surname><given-names>AR</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Hwang</surname><given-names>ST</given-names></name></person-group><article-title>CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via <italic>&#x003b2;</italic>1 integrin</article-title><source><italic>Cancer Research</italic></source><year>2003</year><volume>63</volume><issue>20</issue><fpage>6751</fpage><lpage>6757</lpage><pub-id pub-id-type="pmid">14583470</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chinni</surname><given-names>SR</given-names></name><name><surname>Sivalogan</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><etal/></person-group><article-title>CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12</article-title><source><italic>Prostate</italic></source><year>2006</year><volume>66</volume><issue>1</issue><fpage>32</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">16114056</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cristillo</surname><given-names>AD</given-names></name><name><surname>Highbarger</surname><given-names>HC</given-names></name><name><surname>Dewar</surname><given-names>RL</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name><name><surname>Golding</surname><given-names>H</given-names></name><name><surname>Bierer</surname><given-names>BE</given-names></name></person-group><article-title>Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element</article-title><source><italic>FASEB Journal</italic></source><year>2002</year><volume>16</volume><issue>3</issue><fpage>354</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">11874984</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer</article-title><source><italic>Cancer Letters</italic></source><year>2007</year><volume>253</volume><issue>1</issue><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17306924</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helbig</surname><given-names>G</given-names></name><name><surname>Christopherson</surname><given-names>KW</given-names><suffix>II</suffix></name><name><surname>Bhat-Nakshatri</surname><given-names>P</given-names></name><etal/></person-group><article-title>NF-<italic>&#x003ba;</italic>B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>24</issue><fpage>21631</fpage><lpage>21638</lpage><pub-id pub-id-type="pmid">12690099</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>J&#x000f6;hrer</surname><given-names>K</given-names></name><name><surname>Zelle-Rieser</surname><given-names>C</given-names></name><name><surname>Perathoner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma</article-title><source><italic>Clinical Cancer Research</italic></source><year>2005</year><volume>11</volume><issue>7</issue><fpage>2459</fpage><lpage>2465</lpage><pub-id pub-id-type="pmid">15814620</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Kazama</surname><given-names>S</given-names></name><name><surname>Nagawa</surname><given-names>H</given-names></name></person-group><article-title>Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma</article-title><source><italic>Breast Cancer Research</italic></source><year>2003</year><volume>5</volume><issue>5</issue><fpage>R144</fpage><lpage>R150</lpage><pub-id pub-id-type="pmid">12927045</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>SH</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Bolden</surname><given-names>S</given-names></name><name><surname>Wingo</surname><given-names>PA</given-names></name></person-group><article-title>Cancer statistics, 1999</article-title><source><italic>CA: A Cancer Journal for Clinicians</italic></source><year>1999</year><volume>49</volume><issue>1</issue><fpage>8</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10200775</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laverdiere</surname><given-names>C</given-names></name><name><surname>Hoang</surname><given-names>BH</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma</article-title><source><italic>Clinical Cancer Research</italic></source><year>2005</year><volume>11</volume><issue>7</issue><fpage>2561</fpage><lpage>2567</lpage><pub-id pub-id-type="pmid">15814634</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis</article-title><source><italic>Cancer Cell</italic></source><year>2004</year><volume>6</volume><issue>5</issue><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">15542430</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>MA</given-names></name><name><surname>Ohh</surname><given-names>M</given-names></name></person-group><article-title>von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer</article-title><source><italic>American Journal of Nephrology</italic></source><year>2004</year><volume>24</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">14654728</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>SA</given-names></name><name><surname>Christopherson</surname><given-names>KW</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Kopelovich</surname><given-names>L</given-names></name><name><surname>Goulet</surname><given-names>RJ</given-names><suffix>Jr.</suffix></name><name><surname>Nakshatri</surname><given-names>H</given-names></name></person-group><article-title>Understanding the metastatic switch in breast cancer: role of tumor suppressor p53 on expression of CXCR4, a chemokine receptor involved in site-specific metastasis</article-title><comment>Proceedings of the American Association for Cancer Research, vol. 45, Abstract #3331, 2004</comment></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Doi</surname><given-names>R</given-names></name><name><surname>Koizumi</surname><given-names>M</given-names></name><etal/></person-group><article-title>CXCR4 antagonist inhibits stromall cell-derived factor 1-induced migration and invasion of human pancreatic cancer</article-title><source><italic>Molecular Cancer Therapeutics</italic></source><year>2004</year><volume>3</volume><issue>1</issue><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">14749473</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moriuchi</surname><given-names>M</given-names></name><name><surname>Moriuchi</surname><given-names>H</given-names></name><name><surname>Turner</surname><given-names>W</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry</article-title><source><italic>The Journal of Immunology</italic></source><year>1997</year><volume>159</volume><issue>9</issue><fpage>4322</fpage><lpage>4329</lpage><pub-id pub-id-type="pmid">9379028</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bander</surname><given-names>NH</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name></person-group><article-title>Renal-cell carcinoma</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1996</year><volume>335</volume><issue>12</issue><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">8778606</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group><article-title>Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial Sloan-Kettering Cancer Center experience</article-title><source><italic>Clinical Cancer Research</italic></source><year>2004</year><volume>10</volume><issue>18</issue><fpage>6302s</fpage><lpage>6303s</lpage><pub-id pub-id-type="pmid">15448021</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>C</given-names></name></person-group><article-title>CXCR4: chemokine receptor extraordinaire</article-title><source><italic>Immunological Reviews</italic></source><year>2000</year><volume>177</volume><issue>1</issue><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">11138774</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Mestas</surname><given-names>J</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis</article-title><source><italic>Molecular Cancer</italic></source><year>2006</year><volume>5, article 56</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16403226</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>PH</given-names></name><name><surname>Chaganti</surname><given-names>RSK</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name></person-group><article-title>Targeted therapy for metastatic renal cell carcinoma</article-title><source><italic>British Journal of Cancer</italic></source><year>2006</year><volume>94</volume><issue>5</issue><fpage>614</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">16465192</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>RJ</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Lutz</surname><given-names>M</given-names></name><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Keane</surname><given-names>MP</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name></person-group><article-title>The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases</article-title><source><italic>American Journal of Respiratory and Critical Care Medicine</italic></source><year>2003</year><volume>167</volume><issue>12</issue><fpage>1676</fpage><lpage>1686</lpage><pub-id pub-id-type="pmid">12626353</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>RJ</given-names></name><name><surname>Mestas</surname><given-names>J</given-names></name><name><surname>Gharaee-Kermani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1<italic>&#x003b1;</italic></article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>23</issue><fpage>22473</fpage><lpage>22481</lpage><pub-id pub-id-type="pmid">15802268</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Premack</surname><given-names>BA</given-names></name><name><surname>Schall</surname><given-names>TJ</given-names></name></person-group><article-title>Chemokine receptors: gateways to inflammation and infection</article-title><source><italic>Nature Medicine</italic></source><year>1996</year><volume>2</volume><issue>11</issue><fpage>1174</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">8898734</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>CL</given-names></name><name><surname>Tan</surname><given-names>EY</given-names></name><name><surname>Blay</surname><given-names>J</given-names></name></person-group><article-title>Adenosin increases cell-surface CXCR4 expression on HT-29 human colorectal carcinoma cells</article-title><comment>Proceedings of the American Association for Cancer Research, vol. 45, Abstract #3330, 2004</comment></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Muul</surname><given-names>LM</given-names></name><etal/></person-group><article-title>A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1987</year><volume>316</volume><issue>15</issue><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">3493432</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salcedo</surname><given-names>R</given-names></name><name><surname>Wasserman</surname><given-names>K</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1<italic>&#x003b1;</italic></article-title><source><italic>American Journal of Pathology</italic></source><year>1999</year><volume>154</volume><issue>4</issue><fpage>1125</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">10233851</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schimanski</surname><given-names>CC</given-names></name><name><surname>Schwald</surname><given-names>S</given-names></name><name><surname>Simiantonaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer</article-title><source><italic>Clinical Cancer Research</italic></source><year>2005</year><volume>11</volume><issue>5</issue><fpage>1743</fpage><lpage>1750</lpage><pub-id pub-id-type="pmid">15755995</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staller</surname><given-names>P</given-names></name><name><surname>Sulitkova</surname><given-names>J</given-names></name><name><surname>Lisztwan</surname><given-names>J</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Oakeley</surname><given-names>EJ</given-names></name><name><surname>Krek</surname><given-names>W</given-names></name></person-group><article-title>Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL</article-title><source><italic>Nature</italic></source><year>2003</year><volume>425</volume><issue>6955</issue><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">13679920</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name></person-group><article-title>The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis</article-title><source><italic>Surgical Oncology Clinics of North America</italic></source><year>2001</year><volume>10</volume><issue>2</issue><fpage>383</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">11382593</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terada</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Hakoda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases</article-title><source><italic>Laboratory Investigation</italic></source><year>2003</year><volume>83</volume><issue>5</issue><fpage>665</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">12746476</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Twitchell</surname><given-names>DD</given-names></name><name><surname>London</surname><given-names>NR</given-names><suffix>Jr.</suffix></name><name><surname>Tomer</surname><given-names>DP</given-names></name><name><surname>Tomer</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>BK</given-names></name><name><surname>O'Neill</surname><given-names>KL</given-names></name></person-group><article-title>Tannic acid prevents angiogenesis in vivo by inhibiting CXCR4/SDF-1 alpha binding in breast cancer cells</article-title><comment>Proceedings of the American Association for Cancer Research, vol. 45, Abstract #51, 2004</comment></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>D</given-names></name><name><surname>Begum</surname><given-names>N-M</given-names></name><name><surname>Almofti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma</article-title><source><italic>Experimental Cell Research</italic></source><year>2003</year><volume>290</volume><issue>2</issue><fpage>289</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">14567988</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>O</given-names></name><name><surname>Pappo</surname><given-names>O</given-names></name><name><surname>Safadi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus</article-title><source><italic>European Journal of Immunology</italic></source><year>2004</year><volume>34</volume><issue>4</issue><fpage>1164</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">15048728</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>E</given-names></name><name><surname>Roderiquez</surname><given-names>G</given-names></name><name><surname>Calvert</surname><given-names>V</given-names></name><name><surname>Alvarez</surname><given-names>R</given-names></name><name><surname>Norcross</surname><given-names>MA</given-names></name></person-group><article-title>Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>52</issue><fpage>49236</fpage><lpage>49243</lpage><pub-id pub-id-type="pmid">11668182</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wehler</surname><given-names>T</given-names></name><name><surname>Wolfert</surname><given-names>F</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease</article-title><source><italic>Oncology Reports</italic></source><year>2006</year><volume>16</volume><issue>6</issue><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">17089032</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Jackson</surname><given-names>E</given-names></name><name><surname>Woerner</surname><given-names>BM</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name><name><surname>Rubin</surname><given-names>JB</given-names></name></person-group><article-title>Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo</article-title><source><italic>Cancer Research</italic></source><year>2007</year><volume>67</volume><issue>2</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17234775</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagzag</surname><given-names>D</given-names></name><name><surname>Krishnamachary</surname><given-names>B</given-names></name><name><surname>Yee</surname><given-names>H</given-names></name><etal/></person-group><article-title>Stromal cell-derived factor-1<italic>&#x003b1;</italic> and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor</article-title><source><italic>Cancer Research</italic></source><year>2005</year><volume>65</volume><issue>14</issue><fpage>6178</fpage><lpage>6188</lpage><pub-id pub-id-type="pmid">16024619</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Thefigure depicts <italic>CXCR</italic>4 expression in healthy kidney and cancer samples. Whileglomeruli did not depict any <italic>CXCR</italic>4 expression, tubuli did reveal amedium-strong predominantly cytoplasmic <italic>CXCR</italic>4 expression. All cancersamples did reveal a cytoplasmatic expression of <italic>CXCR</italic>4 ranging from weak(34%) to medium (42%) and strong (24%).</p></caption><graphic xlink:href="JO2008-626340.001"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patient and tumor characteristics dependent on intensity of <italic>CXCR</italic>4 expression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1"><italic>CXCR</italic>4 expression</th><th align="center" rowspan="2" colspan="1">Statistics</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Weak</th><th align="center" rowspan="1" colspan="1">Medium</th><th align="center" rowspan="1" colspan="1">Strong</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> Total number </td><td align="center" rowspan="1" colspan="1"><bold>39</bold> (34%)</td><td align="center" rowspan="1" colspan="1"><bold>47</bold> (42%)</td><td align="center" rowspan="1" colspan="1"><bold>27</bold> (24%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Average age (years)</td><td align="center" colspan="2" rowspan="1">63.8</td><td align="center" rowspan="1" colspan="1">66.3</td><td align="center" rowspan="1" colspan="1"><italic>n.s.</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"> Gender </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Female</td><td align="center" colspan="2" rowspan="1">36 (42%)</td><td align="center" rowspan="1" colspan="1">8 (30%)</td><td align="center" rowspan="2" colspan="1"><italic>n.s.</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>Male</td><td align="center" colspan="2" rowspan="1">50 (58%)</td><td align="center" rowspan="1" colspan="1">19 (70%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Grading </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>1/2</td><td align="center" colspan="2" rowspan="1">65 (78%)</td><td align="center" rowspan="1" colspan="1">11 (41%)</td><td align="center" rowspan="2" colspan="1"><italic>P</italic> = .0005</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>3/4</td><td align="center" colspan="2" rowspan="1">18 (22%)</td><td align="center" rowspan="1" colspan="1">15 (59%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> T-status </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>1/2</td><td align="center" colspan="2" rowspan="1">64 (76%)</td><td align="center" rowspan="1" colspan="1">15 (56%)</td><td align="center" rowspan="2" colspan="1"><italic>P</italic> = .039</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x02003;</italic>3/4</td><td align="center" colspan="2" rowspan="1">20 (24%)</td><td align="center" rowspan="1" colspan="1">12 (44%)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Average size (cm)</td><td align="center" colspan="2" rowspan="1">5.7</td><td align="center" rowspan="1" colspan="1">6.0</td><td align="center" rowspan="1" colspan="1"><italic>n.s.</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"> Survival (months)</td><td align="center" colspan="2" rowspan="1">29.7</td><td align="center" rowspan="1" colspan="1">36.8</td><td align="center" rowspan="1" colspan="1"><italic>n.s.</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"> Average creatinin (mg/dl)</td><td align="center" colspan="2" rowspan="1"> 1.11</td><td align="center" rowspan="1" colspan="1">1.07</td><td align="center" rowspan="1" colspan="1"><italic>n.s.</italic></td></tr><tr><td align="left" rowspan="2" colspan="1"> Average hemoglobin (g/dl)</td><td align="center" colspan="2" rowspan="2">14.32</td><td align="center" rowspan="2" colspan="1">13.25</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .019<italic>(1-sided)</italic></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .039<italic>(2-sided)</italic></td></tr><tr><td align="left" rowspan="2" colspan="1"> Average thrombocytes (/nl)</td><td align="center" colspan="2" rowspan="2">271</td><td align="center" rowspan="2" colspan="1"> 313</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .089<italic>(1-sided)</italic></td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .18<italic>(2-sided)</italic></td></tr></tbody></table></table-wrap></floats-wrap></article>